Hematologic Malignancy
Digestive System Mature B-Cell Neoplasm
CI-CAN-00000818Explore in graph →
HematologicNon-malignant5 active trials
- NCIt
- C213874
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000818Explore in graph →
Clinical trials
10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06454149 | Cohort Study for Gastric MALT Lymphoma(HUG-MALToma) | recruiting | — | 300 | Seoul National University HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma |
Data updated yesterdaySource updated Sep 29, 2026source: clinicaltrials
| recruiting |
| Phase 2 |
| 160 |
| Fudan UniversityOTHER |
| 1 |
| Feb 23, 2024 |
| clinicaltrials |